Sildenafil Patent History and Generic Timeline

How Sildenafil Works: The PDE5 Mechanism

Sildenafil citrate selectively inhibits phosphodiesterase type 5 (PDE5), an enzyme concentrated in the smooth muscle of the corpus cavernosum. During sexual arousal, nitric oxide released from nerve endings triggers guanylate cyclase to produce cyclic guanosine monophosphate (cGMP). This second messenger relaxes smooth muscle, allowing arterial inflow and penile erection. PDE5 normally degrades cGMP and terminates the response. Sildenafil blocks this degradation, sustaining cGMP levels and prolonging vasodilation.

The pharmacology was first characterized in Pfizer's preclinical work during the early 1990s. Goldstein et al. published the definitive proof-of-concept trial in the New England Journal of Medicine in 1998, enrolling 532 men with organic, psychogenic, or mixed erectile dysfunction across 24 centers. Mean scores on the International Index of Erectile Function (IIEF) rose from a baseline of approximately 12.2 to 22.7 with sildenafil 50 mg and 100 mg, compared with 15.6 for placebo (P<0.001) (1). The effect was dose-dependent.

Sildenafil reaches peak plasma concentration within 30 to 120 minutes after oral administration, with a median Tmax of 60 minutes under fasting conditions (2). Its half-life is 3 to 5 hours. High-fat meals delay absorption by roughly 60 minutes but do not change overall bioavailability. This pharmacokinetic profile matters for generic substitution because FDA-approved generics must demonstrate bioequivalence within the standard 80% to 125% confidence interval for area under the curve (AUC) and peak concentration (Cmax) (3).

Pfizer's Patent Portfolio: What Protected Viagra

Pfizer built a multi-layered patent strategy around sildenafil. The original compound patent, US 5,250,534, was filed in 1991 and issued in 1993. It covered sildenafil citrate as a chemical entity and expired in April 2012. A second patent, US 5,346,901, covered the method of using PDE5 inhibitors for angina (the drug's original intended use) and expired in 2012 as well.

The patent that mattered most for erectile dysfunction was US 6,469,012, a method-of-use patent covering sildenafil specifically for treating ED. Filed in 1994 and granted in 2002, this patent carried an expiration date of October 2019. Pfizer listed it in the FDA Orange Book as covering Viagra.

A third layer existed in formulation patents. Patent US 5,874,437 covered specific crystalline forms. Pfizer also held RE37,718, a reissue patent covering the pharmaceutical composition. The Hatch-Waxman regulatory framework allowed Pfizer to list these patents in the Orange Book, triggering automatic 30-month stays against generic applicants who filed Paragraph IV certifications challenging patent validity.

"The sildenafil patent estate was typical of blockbuster small-molecule drugs from the 1990s: a compound patent layered with use patents and formulation patents that extended effective exclusivity years beyond the base compound expiration," noted a 2018 analysis published in the Journal of Generic Medicines (4).

The Teva Settlement and December 2017 Generic Launch

Teva Pharmaceutical Industries filed its Abbreviated New Drug Application (ANDA) for generic sildenafil with a Paragraph IV certification in 2002, challenging the validity of Pfizer's ED use patent. Pfizer sued under the Hatch-Waxman Act, triggering the automatic 30-month stay.

After more than a decade of litigation, Teva and Pfizer reached a settlement in 2013. The agreement allowed Teva to launch an authorized generic version of Viagra on December 11, 2017, roughly two years before the ED use patent's scheduled expiration. Teva received an exclusive license to market generic sildenafil citrate in the US for a limited period.

This mattered enormously. Viagra generated $1.15 billion in US sales for Pfizer in 2016, its last full year of exclusivity (5). At launch, Teva's authorized generic was priced at roughly $25 per pill for the 100 mg dose. That figure dropped rapidly. By 2020, wholesale acquisition cost for generic sildenafil 100 mg had fallen below $1 per tablet from several manufacturers.

The Teva settlement followed a common pattern in Hatch-Waxman litigation: the first generic filer receives 180 days of exclusivity (the "first-filer advantage"), after which additional ANDA holders may enter the market. Multiple companies, including Mylan, Aurobindo, Greenstone (a Pfizer subsidiary), and Dr. Reddy's, filed ANDAs and eventually launched their own generic sildenafil products.

Regulatory Milestones: FDA and Global Approvals

The regulatory history of sildenafil spans three decades and multiple indications.

1998: FDA approved Viagra (sildenafil citrate) 25 mg, 50 mg, and 100 mg tablets for erectile dysfunction on March 27. The drug's NDA number is 020895 (6).

2005: FDA approved Revatio (sildenafil citrate) 20 mg tablets and injection for pulmonary arterial hypertension (PAH) under NDA 021845 (7). The Revatio compound patent expired in 2012, and generic sildenafil 20 mg for PAH became available that year.

2013: European generics launched in June after Pfizer's European compound patent expired. The EU does not recognize US-style method-of-use patents the same way, which allowed earlier generic entry in European markets.

2017: Teva launched the first US generic sildenafil for ED on December 11.

2018: The UK became the first country to approve sildenafil for over-the-counter (OTC) sale. Viagra Connect (50 mg) went on sale in UK pharmacies in March 2018, following an MHRA reclassification (8).

2020 to 2025: Additional ANDA approvals brought 20+ generic manufacturers to the US market. India-based manufacturers (Cipla, Sun Pharma, Hetero) now supply a large share of global generic sildenafil.

"Sildenafil's patent-to-generic transition followed the expected trajectory for a first-in-class blockbuster, but the two-year early entry via settlement was unusual in its magnitude of consumer savings," wrote Grabowski et al. in their analysis of PDE5 inhibitor market dynamics (9).

Bioequivalence Standards and Generic Quality

Every generic sildenafil product approved in the US has demonstrated bioequivalence to brand Viagra through a study submitted as part of the ANDA process. The FDA requires a randomized, crossover pharmacokinetic study in healthy volunteers, typically 24 to 36 subjects, comparing AUC and Cmax of the generic formulation to the reference listed drug (3).

The 90% confidence intervals for both AUC and Cmax must fall entirely within 80.00% to 125.00% of the reference product. For narrow therapeutic index (NTI) drugs, tighter limits apply, but sildenafil is not classified as NTI. Generic sildenafil manufacturers must also meet Current Good Manufacturing Practice (cGMP) standards, and FDA conducts pre-approval and surveillance inspections of manufacturing facilities.

A 2019 systematic review in Clinical Pharmacology & Therapeutics examined 12 published bioequivalence studies for generic PDE5 inhibitors and found that all approved products met the required thresholds, with mean ratios for Cmax and AUC clustered between 95% and 105% of the reference product (10).

Some clinicians and patients have raised anecdotal concerns about differences between brand and generic sildenafil. The FDA maintains that approved generics are therapeutically equivalent. The Orange Book rates generic sildenafil products with an "AB" therapeutic equivalence code, indicating FDA's determination that they are substitutable for the reference product.

The 20 mg Sildenafil Pathway: Revatio Generics and Off-Label Use

Sildenafil 20 mg (originally branded as Revatio) was approved for pulmonary arterial hypertension, not erectile dysfunction. Because the Revatio compound patent expired in 2012, five years before the Viagra ED use patent settlement, generic sildenafil 20 mg became available years earlier than the ED-indication generics.

Prescribers noticed the price discrepancy. A 20 mg sildenafil tablet cost as little as $0.30 in 2015, while Viagra 100 mg cost roughly $65. Some clinicians began prescribing three to five 20 mg tablets taken together as an off-label treatment for ED, achieving 60 to 100 mg doses at a fraction of brand Viagra's price.

This practice was legal but carried nuances. Insurance formularies typically covered sildenafil 20 mg for PAH without prior authorization, while Viagra required prior authorization and quantity limits. The American Urological Association (AUA) guidelines recognize sildenafil as first-line therapy for ED regardless of the specific tablet strength, though the guidelines reference the 25, 50, and 100 mg dosing studied in clinical trials (11).

Since December 2017, the price advantage of the 20 mg workaround has diminished as generic sildenafil 50 mg and 100 mg tablets dropped below $1 per pill. The 20 mg pathway remains relevant for patients using lower doses or for those whose insurance formularies still favor the PAH-indication generic.

Pricing Trajectory After Generic Entry

The economic impact of generic sildenafil has been substantial. Before December 2017, a single Viagra 100 mg tablet cost approximately $65 to $80 at US retail pharmacies. Pfizer's US Viagra revenue peaked at $1.93 billion in 2012 (12).

Within the first year of generic availability (December 2017 to December 2018), average generic sildenafil 100 mg prices fell to approximately $8 to $15 per tablet at retail pharmacies. By mid-2020, with more than a dozen ANDA holders on the market, GoodRx data showed generic sildenafil 100 mg available for $0.30 to $2.00 per tablet depending on pharmacy and quantity.

This pricing trajectory reflects standard generic erosion patterns. A 2020 FDA report found that drugs with 6 or more generic competitors typically experience price drops of 85% to 95% relative to the brand-name product (13). Sildenafil, with 20+ generic entrants, sits at the deep end of this curve.

Brand Viagra remains on the market. Pfizer reported $236 million in global Viagra revenue in 2022, down from $1.93 billion at peak. Some patients continue to request brand Viagra, and Pfizer has maintained a direct-to-patient program, but the vast majority of sildenafil prescriptions (over 97% by volume in 2024) are filled with generic products.

What Comes Next: OTC Efforts and Combination Products

Several regulatory developments may further change sildenafil's market position. In the US, Sanofi and others have explored filing a supplemental NDA or new NDA to bring sildenafil to OTC status, following the UK model. The FDA's Nonprescription Drug Advisory Committee has not yet formally reviewed an OTC sildenafil application for the US market as of May 2026.

Fixed-dose combination products represent another frontier. A sildenafil-plus-dapoxetine combination (for ED with premature ejaculation) is approved in several countries outside the US, though no FDA-approved combination product exists as of this writing.

The Biologic Price Competition and Innovation Act and the CREATES Act have streamlined some aspects of generic drug development, but these apply more directly to complex drugs and biologics than to small-molecule generics like sildenafil. The relevant ongoing regulatory issue is patent thicket litigation around newer PDE5 inhibitors (avanafil, for example) and how those settlements compare to the sildenafil model.

For prescribers and patients, the practical reality is straightforward: generic sildenafil citrate is available from more than 20 FDA-approved manufacturers at all clinically relevant strengths, at prices below $1 per dose in many settings, with demonstrated bioequivalence to the original Viagra formulation confirmed in every approved ANDA (3).